MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
4.160
+0.120
+2.97%
After Hours: 4.140 -0.02 -0.48% 16:50 02/26 EST
OPEN
4.020
PREV CLOSE
4.040
HIGH
4.180
LOW
3.960
VOLUME
877.48K
TURNOVER
0
52 WEEK HIGH
9.17
52 WEEK LOW
2.605
MARKET CAP
602.25M
P/E (TTM)
-2.6665
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADPT last week (0219-0223)?
Weekly Report · 20h ago
Adaptive Biotechnologies: A Post Earnings Assessment
Seeking Alpha · 1d ago
Aristotle Capital Focus Growth Q4 2023 Commentary
Aristotle Capital Focus Growth Composite posted a total return of 15.02% gross of fees in the fourth quarter of 2023. The U.S. Equity market rebounded, as the S&P 500 Index rose 11.69% during the period. Real Estate, Utilities and Information Technology were the best-performing sectors.
Seeking Alpha · 1d ago
Aristotle Capital Large Cap Growth Q4 2023 Commentary
Seeking Alpha · 1d ago
Analysts’ Top Healthcare Picks: RxSight (RXST), Adaptive Biotechnologies (ADPT)
RxSight (RXST) and Adaptive Biotechnologies (ADPT) have 2 analysts maintaining Buy ratings. BTIG analyst Ryan Zimmerman maintained a Buy rating on RxSight and set a price target of $61.00. The company's shares closed yesterday at $54.95.
TipRanks · 6d ago
Weekly Report: what happened at ADPT last week (0212-0216)?
Weekly Report · 02/19 09:29
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) analysts have downgraded their near-term revenue and earnings estimates for the business. The consensus price target for the company has fallen 17% to US$7.17. The analysts have also increased their loss per share forecasts for this year. The company is now expected to grow sales slower than the wider market in 2024.
Simply Wall St · 02/17 12:06
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
TipRanks · 02/16 12:39
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.